DDInter8 DDInter1435
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Abiraterone {u} (Compound) resembles {v} (Compound) Testosterone
Abiraterone {u} (Compound) treats {v} (Disease) prostate cancer
Abiraterone {u} (Compound) binds {v} (Gene) ABCC1
Abiraterone {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Torasemide
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Abiraterone (Compound) resembles Testosterone (Compound)
Abiraterone (Compound) treats prostate cancer (Disease)
Abiraterone (Compound) binds ABCC1 (Gene)
Abiraterone (Compound) causes Hypokalaemia (Side Effect)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Torasemide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Abiraterone may lead to a major life threatening interaction when taken with Dofetilide
Abiraterone may lead to a major life threatening interaction when taken with Ivabradine